Biomarkers in Early Response to Brolucizumab on Pigment Epithelium Detachment Associated with Exudative Age-Related Macular Degeneration.
Brolucizumab
OCT angiography
age-related macular degeneration
exudative AMD
innovative biotechnologies
personalized medicine
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
10 Jun 2021
10 Jun 2021
Historique:
received:
06
05
2021
revised:
05
06
2021
accepted:
07
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
The purpose of this study was to describe early changes in the morphology of pigment epithelium detachments (PED) after an intravitreal injection of Brolucizumab into eyes with macular neovascularization secondary to exudative age-related macular degeneration (e-AMD). We included twelve eyes of 12 patients with PED secondary to e-AMD which were not responding to prior anti-VEGF treatments. An ophthalmic examination and an assessment of PED-horizontal maximal diameter (PED-HMD), PED-maximum high (PED-MH) and macular neovascularization (MNV) flow area (MNV-FA) by the means of structural optical coherence tomography (OCT) and OCT Angiography (OCT-A) were performed at baseline, as well as 1, 7, 14 and 30 days after the injection. The mean age of the population of study was 78.4 (SD ± 4.8). The mean number of previous Ranibizumab or Aflibercept injections was 13 (SD ± 8). At the last follow-up visit, the PED-HMD did not significantly change ( A single Brolucizumab injection was able to determine the short-term effects on PEDs' anatomical features of eyes with an unresponsive e-AMD.
Sections du résumé
BACKGROUND
BACKGROUND
The purpose of this study was to describe early changes in the morphology of pigment epithelium detachments (PED) after an intravitreal injection of Brolucizumab into eyes with macular neovascularization secondary to exudative age-related macular degeneration (e-AMD).
METHOD
METHODS
We included twelve eyes of 12 patients with PED secondary to e-AMD which were not responding to prior anti-VEGF treatments. An ophthalmic examination and an assessment of PED-horizontal maximal diameter (PED-HMD), PED-maximum high (PED-MH) and macular neovascularization (MNV) flow area (MNV-FA) by the means of structural optical coherence tomography (OCT) and OCT Angiography (OCT-A) were performed at baseline, as well as 1, 7, 14 and 30 days after the injection.
RESULTS
RESULTS
The mean age of the population of study was 78.4 (SD ± 4.8). The mean number of previous Ranibizumab or Aflibercept injections was 13 (SD ± 8). At the last follow-up visit, the PED-HMD did not significantly change (
CONCLUSIONS
CONCLUSIONS
A single Brolucizumab injection was able to determine the short-term effects on PEDs' anatomical features of eyes with an unresponsive e-AMD.
Identifiants
pubmed: 34200829
pii: biomedicines9060668
doi: 10.3390/biomedicines9060668
pmc: PMC8230427
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2006 Oct 5;355(14):1419-31
pubmed: 17021318
Dan Med J. 2017 Nov;64(11):
pubmed: 29115208
Am J Ophthalmol Case Rep. 2020 Apr 02;18:100687
pubmed: 32280811
Retina. 2018 Sep;38(9):1759-1769
pubmed: 29293207
Eye (Lond). 2019 Sep;33(9):1466-1471
pubmed: 30971814
Br J Ophthalmol. 2021 Apr 12;:
pubmed: 33846161
Int Med Case Rep J. 2020 May 11;13:145-152
pubmed: 32494207
IEEE J Biomed Health Inform. 2020 Dec;24(12):3456-3465
pubmed: 32750929
Sci Rep. 2018 Oct 23;8(1):15631
pubmed: 30353107
Retina. 2020 Jul;40(7):1224-1233
pubmed: 31259809
Biomed Opt Express. 2020 Jan 14;11(2):927-944
pubmed: 32133230
Retina. 2021 Apr 01;:
pubmed: 33830960
Retina. 2011 Mar;31(3):553-8
pubmed: 21343873
Transl Vis Sci Technol. 2020 Feb 14;9(3):18
pubmed: 32714644
Acta Ophthalmol. 2017 Jun;95(4):414-420
pubmed: 28133946
Sci Rep. 2020 Sep 22;10(1):15434
pubmed: 32963300
Antioxidants (Basel). 2020 Nov 20;9(11):
pubmed: 33233726
Eur J Ophthalmol. 2019 Mar;29(2):239-243
pubmed: 29991290
J Clin Med. 2020 Sep 15;9(9):
pubmed: 32942540
Adv Exp Med Biol. 2021;1256:33-66
pubmed: 33847997
Ophthalmology. 2020 Mar;127(3):394-409
pubmed: 31708275
Am J Ophthalmol. 2021 Apr;224:321-331
pubmed: 33359715
Int J Mol Sci. 2021 Mar 27;22(7):
pubmed: 33801777
Am J Ophthalmol. 2015 Jul;160(1):6-16
pubmed: 25887628
F1000Res. 2017 Mar 9;6:245
pubmed: 28529701
Br J Ophthalmol. 2013 Nov;97(11):1443-6
pubmed: 23966368
Int J Mol Sci. 2020 Dec 23;22(1):
pubmed: 33374679
Curr Drug Deliv. 2019;16(3):226-232
pubmed: 30381074
Sci Rep. 2021 Mar 11;11(1):5743
pubmed: 33707539
Surv Ophthalmol. 2007 May-Jun;52(3):227-43
pubmed: 17472800
Ophthalmology. 2012 Dec;119(12):2537-48
pubmed: 23084240
Graefes Arch Clin Exp Ophthalmol. 2021 Apr 26;:
pubmed: 33900443
Ophthalmol Retina. 2020 May;4(5):471-480
pubmed: 32245653
Retina. 2015 Jul;35(7):1292-302
pubmed: 25830697
Br J Ophthalmol. 2015 Feb;99(2):220-6
pubmed: 25193672
Expert Opin Biol Ther. 2021 May;21(5):553-561
pubmed: 33899632
Ophthalmology. 2020 Jan;127(1):72-84
pubmed: 30986442
Diagnostics (Basel). 2021 Feb 01;11(2):
pubmed: 33535592
J Clin Med. 2020 Dec 09;9(12):
pubmed: 33316923
Ophthalmology. 2017 Sep;124(9):1296-1304
pubmed: 28551167
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
Antioxidants (Basel). 2020 Nov 20;9(11):
pubmed: 33233546
Br J Ophthalmol. 2012 May;96(5):752-6
pubmed: 22329913
Eye (Lond). 2015 Jun;29(6):721-31
pubmed: 25882328
N Engl J Med. 2011 May 19;364(20):1897-908
pubmed: 21526923
Med Clin North Am. 2021 May;105(3):473-491
pubmed: 33926642
Retina. 2018 Jun;38(6):1100-1109
pubmed: 28520639
N Engl J Med. 2004 Dec 30;351(27):2805-16
pubmed: 15625332
Eur J Ophthalmol. 2021 Mar;31(2):514-520
pubmed: 32228026
Eye (Lond). 2018 Apr;32(4):734-742
pubmed: 29303152